Companies Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals (DAWN): executive pay, fiscal 2024
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Day One Biopharmaceuticals, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $5,074,256FY2022
- $6,913,959FY2023
- $6,560,577FY2024
CEO total pay was $6,560,577 in fiscal 2024, down from $6,913,959 in fiscal 2023.
FY2024: salary $680,000 · bonus $0 · stock awards $2,700,280 · option awards $2,664,697
Executives and directors
Adam Dubow · General CounselJeremy Bender · CEOCharles York · CFOSamuel Blackman · ExecutiveDaniel Becker · Former director (through FY2024)Garry Nicholson · Chair of the BoardHabib Dable · Independent DirectorJohn Josey · Independent DirectorMichael Gladstone · Independent DirectorNatalie Holles · Independent DirectorScott Garland · Independent DirectorWilliam Grossman · Independent Director
Frequently asked questions
Who was the highest-paid executive at Day One Biopharmaceuticals, Inc. in fiscal 2024?
As disclosed, Jeremy Bender (Chief Executive Officer and President) was the highest-paid executive at Day One Biopharmaceuticals, Inc. in fiscal 2024, with total compensation of $6,560,577.
What is Day One Biopharmaceuticals, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Day One Biopharmaceuticals, Inc.'s CEO-to-median employee pay ratio was 17:1.
How much does Day One Biopharmaceuticals, Inc. spend in total on board compensation for fiscal 2024?
As disclosed, Day One Biopharmaceuticals, Inc. reported total board compensation of $471,055 for fiscal 2024.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Jeremy Bender | $680,000 | $0 | $2,700,280 | $2,664,697 | $501,800 | $0 | $13,800 | $6,560,577 |
| Chief Executive Officer and President | ||||||||
| Charles York | 541,000 | 0 | 1,530,640 | 1,511,240 | 299,400 | 0 | 13,800 | 3,896,080 |
| Chief Operating Officer and Chief Financial Officer | ||||||||
| Samuel Blackman | 527,000 | 0 | 1,400,680 | 1,381,724 | 291,700 | 0 | 13,800 | 3,614,904 |
| Co-Founder and Head of Research and Development | ||||||||
| Adam Dubow | 455,000 | 0 | 851,960 | 840,954 | 223,900 | 0 | 13,800 | 2,385,614 |
| General Counsel, Chief Compliance Officer and Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Jeremy Bender | $6,560,577 | $6,913,959 | $5,074,256 | ↓ −353,382 |
| Charles York | 3,896,080 | 3,546,093 | 2,307,251 | ↑ +349,987 |
| Samuel Blackman | 3,614,904 | 2,485,392 | 2,064,997 | ↑ +1,129,512 |
| Adam Dubow | 2,385,614 | 2,773,253 | — | ↓ −387,639 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The objective is to hire, reward, and retain world-class talent to execute strategy and develop new medicines. Compensation is tied to performance and stock price, with the vast majority of target total direct compensation being variable and at risk (approx. 90% for CEO, 84% for other NEOs).
| CEO STI target (% of salary) | NaN% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia Inc. |
| Clawback policy | Adopted in December 2023 in compliance with SEC Rule 10D-1 and Nasdaq rules. Provides for recovery of incentive-based compensation in the event of a financial restatement. Clawback Period is defined as the three completed fiscal years immediately prior to the determination of a restatement requirement. |
| Anti-hedging | The Insider Trading Policy bars covered persons from hedging the company's securities. |
| Anti-pledging | The Insider Trading Policy bars covered persons from pledging the company's securities. |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2024
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Charles York | OPTION | 2024-01-05 | — | — | 162,000 | — | $1,511,240 |
| Jeremy Bender | RSU | 2024-01-05 | — | — | 187,000 | — | 2,700,280 |
| Samuel Blackman | RSU | 2024-01-05 | — | — | 97,000 | — | 1,400,680 |
| Adam Dubow | RSU | 2024-01-05 | — | — | 59,000 | — | 851,960 |
| Charles York | RSU | 2024-01-05 | — | — | 106,000 | — | 1,530,640 |
| Samuel Blackman | OPTION | 2024-01-05 | — | — | 148,000 | — | 1,381,724 |
| Jeremy Bender | OPTION | 2024-01-05 | — | — | 286,000 | — | 2,664,697 |
| Adam Dubow | OPTION | 2024-01-05 | — | — | 90,000 | — | 840,954 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Charles York | $1,530,640 | $0 | $1,511,240 | 0.0% |
| Jeremy Bender | 2,700,280 | 0 | 2,664,697 | 0.0% |
| Samuel Blackman | 1,400,680 | 0 | 1,381,724 | 0.0% |
| Adam Dubow | 851,960 | 0 | 840,954 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Samuel Blackman | RSU | 4,756 | — | $60,259 |
| Samuel Blackman | RSU | 5,144 | — | 65,174 |
| Charles York | RSU | 5,500 | — | 69,685 |
| Samuel Blackman | RSU | 11,504 | — | 145,756 |
| Adam Dubow | RSU | 14,000 | — | 177,380 |
| Charles York | RSU | 14,066 | — | 178,216 |
| Jeremy Bender | RSU | 14,256 | — | 180,624 |
| Charles York | RSU | 18,000 | — | 228,060 |
| Samuel Blackman | Option | 18,907 | 16 | — |
| Adam Dubow | RSU | 23,702 | — | 300,304 |
| Jeremy Bender | RSU | 27,260 | — | 345,384 |
| Samuel Blackman | Option | 36,569 | 14.26 | — |
| Charles York | Option | 37,007 | 16 | — |
| Samuel Blackman | Option | 37,500 | 23.41 | — |
| Jeremy Bender | RSU | 38,000 | — | 481,460 |
| Charles York | Option | 40,898 | 14.26 | — |
| Adam Dubow | RSU | 44,252 | — | 560,673 |
| Adam Dubow | Option | 46,875 | 23.41 | — |
| Charles York | Option | 60,425 | 23.41 | — |
| Adam Dubow | Option | 69,375 | 14.44 | — |
| Samuel Blackman | RSU | 72,752 | — | 921,768 |
| Charles York | RSU | 79,500 | — | 1,007,265 |
| Jeremy Bender | Option | 107,523 | 14.26 | — |
| Samuel Blackman | Option | 114,087 | 14.44 | — |
| Charles York | Option | 124,875 | 14.44 | — |
| Jeremy Bender | Option | 127,091 | 23.41 | — |
| Jeremy Bender | RSU | 140,252 | — | 1,776,993 |
| Adam Dubow | Option | 141,632 | 21.14 | — |
| Jeremy Bender | Option | 143,166 | 16 | — |
| Jeremy Bender | Option | 220,462 | 14.44 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| William GrossmanIndependent · Compensation | $45,597 | — | $866,300 | — | — | $911,897 |
| Habib DableIndependent · Nominating and Corporate Governance | 43,722 | — | 866,300 | — | — | 910,022 |
| Garry NicholsonIndependent · Board Chair · Compensation · Nominating and Corporate Governance | 84,875 | — | 278,600 | — | — | 363,475 |
| Saira RamasastryIndependent · Audit (Chair) | 61,750 | — | 278,600 | — | — | 340,350 |
| Natalie HollesIndependent · Compensation (Chair) | 59,250 | — | 278,600 | — | — | 337,850 |
| John JoseyIndependent · Nominating and Corporate Governance (Chair) | 53,625 | — | 278,600 | — | — | 332,225 |
| Scott GarlandIndependent · Audit | 51,750 | — | 278,600 | — | — | 330,350 |
| Michael GladstoneIndependent · Audit · Not standing for re-election | 51,750 | — | 278,600 | — | — | 330,350 |
| Daniel BeckerIndependent · Not standing for re-election · Departed during FY | 18,736 | — | 0 | — | — | 18,736 |
| Jeremy BenderEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $43,500 |
|---|---|
| Annual equity retainer | $312,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $471,055 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $471,055 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Day One Biopharmaceuticals as a peer
Companies that benchmark against DAWN
16 companies name DAWN as a compensation peer
- Arcus Biosciences, Inc.RCUSFY2025
- ARROWHEAD PHARMACEUTICALS, INC.ARWRFY2025
- ARS Pharmaceuticals, Inc.SPRYFY2025
- Aurinia Pharmaceuticals Inc.AUPHFY2025
- Cogent Biosciences, Inc.COGTFY2025
- Kura Oncology, Inc.KURAFY2025
- LIGAND PHARMACEUTICALS INCLGNDFY2025
- OCULAR THERAPEUTIX, INCOCULFY2025
- Perspective Therapeutics, Inc.CATXFY2025
- PLIANT THERAPEUTICS, INC.PLRXFY2025
- PRECIGEN, INC.PGENFY2025
- Scholar Rock Holding CorpSRRKFY2025
- Syndax Pharmaceuticals IncSNDXFY2025
- Tarsus Pharmaceuticals, Inc.TARSFY2025
- UroGen Pharma Ltd.URGNFY2025
- Xenon Pharmaceuticals Inc.XENEFY2025
Each company listed discloses DAWN in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named DAWN in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2024
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Executive
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Day One Biopharmaceuticals, Inc. | 2024 | Jeremy Bender | $680,000 | $2,700,280 | $2,664,697 | $501,800 | $6,560,577 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
CEO pay ratio
| Ratio (CEO : median employee) | 17 : 1 |
|---|---|
| CEO total compensation | $6,560,577 |
| Median employee compensation | $389,481 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Scott Garland | Director | 2025-11-06 | A | 28,700 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2025-11-06 | A | 309,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2025-11-06 | A | 32,335 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2025-11-06 | A | 32,335 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2025-11-06 | A | 37,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2025-11-06 | A | 28,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Garland | Director | 2025-11-06 | A | 48,072 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2025-11-06 | A | 40,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Garry Nicholson | Director | 2025-11-06 | A | 32,335 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Garry Nicholson | Director | 2025-11-06 | A | 37,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2025-11-06 | A | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-15 | D | 11,687 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-15 | D | 4,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-15 | A | 11,687 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-15 | A | 4,750 | — | — | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2025-11-15 | A | 3,687 | — | — | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2025-11-15 | A | 3,162 | — | — | Common | Form 4 ↗ |
| Charles York | COO and CFO | 2025-11-15 | D | 6,625 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2025-11-15 | D | 6,625 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2025-11-15 | D | 2,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2025-11-15 | — | 3,125 | — | — | 2 insiders, 2 accrual rows | ||
| Charles York | COO and CFO | 2025-11-15 | A | 2,250 | — | — | Common | Form 4 ↗ |
| Charles York | COO and CFO | 2025-11-15 | A | 1,375 | — | — | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2025-11-15 | A | 3,687 | — | — | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2025-11-15 | A | 3,687 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-15 | D | 11,687 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-15 | A | 3,570 | — | — | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2025-11-15 | D | 3,687 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2025-11-15 | D | 3,687 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2025-11-15 | D | 2,963 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2025-11-15 | A | 3,687 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-15 | A | 11,687 | — | — | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2025-11-15 | D | 3,687 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2025-11-15 | D | 3,162 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2025-11-15 | A | 1,750 | — | — | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2025-11-15 | A | 2,963 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-15 | D | 3,570 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2025-11-15 | D | 3,687 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2025-11-15 | A | 6,625 | — | — | Common | Form 4 ↗ |
| Charles York | COO and CFO | 2025-11-15 | A | 6,625 | — | — | Common | Form 4 ↗ |
| Charles York | COO and CFO | 2025-11-17 | D | 4,062 | 9 | 36,212 | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2025-11-17 | D | 3,726 | 9 | 33,216 | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2025-11-17 | D | 4,319 | 9 | 38,503 | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-17 | D | 15,894 | 9 | 141,690 | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-25 | A | 300,000 | 0 | 0 | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-25 | A | 300,000 | 0 | 0 | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-25 | D | 7,225 | 0 | 0 | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-25 | D | 7,225 | 0 | 0 | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-25 | D | 300,000 | 0 | 0 | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-25 | D | 300,000 | 0 | 0 | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-01-30 | A | 110,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Vasconcelles | Head of Research and Dev. | 2026-01-30 | A | 114,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-01-30 | A | 74,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-01-30 | A | 355,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Vasconcelles | Head of Research and Dev. | 2026-01-30 | A | 171,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-01-30 | A | 126,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-01-30 | A | 188,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-01-30 | A | 237,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-01-30 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-01-30 | A | 105,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-02-15 | D | 11,687 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-02-15 | D | 11,688 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-02-15 | A | 14,812 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-02-15 | A | 4,750 | — | — | Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-02-15 | D | 7,875 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-02-15 | D | 6,625 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-02-15 | D | 2,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-02-15 | A | 7,875 | — | — | Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-02-15 | A | 6,625 | — | — | Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-02-15 | A | 2,250 | — | — | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-02-15 | D | 3,687 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-02-15 | — | 1,750 | — | — | 1 insider, 1 accrual row | ||
| Adam Dubow | Gen Counsel & Secretary | 2026-02-15 | A | 3,688 | — | — | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-02-15 | D | 4,625 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-02-15 | A | 3,687 | — | — | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-02-15 | A | 3,688 | — | — | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-02-15 | D | 3,688 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-02-15 | A | 3,687 | — | — | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-02-15 | D | 3,162 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Vasconcelles | Head of Research and Dev. | 2026-02-15 | D | 7,125 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Vasconcelles | Head of Research and Dev. | 2026-02-15 | A | 7,125 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-02-15 | D | 4,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-02-15 | A | 11,687 | — | — | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-02-15 | A | 4,375 | — | — | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-02-15 | A | 1,750 | — | — | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-02-15 | D | 4,375 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-02-15 | D | 3,687 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-02-15 | D | 3,688 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-02-15 | A | 3,162 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-02-15 | D | 14,812 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-02-15 | A | 4,625 | — | — | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-02-15 | D | 2,963 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-02-15 | D | 6,625 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-02-15 | A | 2,963 | — | — | Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-02-15 | A | 6,625 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-02-15 | A | 11,688 | — | — | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-02-17 | D | 5,814 | 12 | 67,448 | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-02-17 | D | 15,459 | 12 | 179,338 | Common | Form 4 ↗ |
| Michael Vasconcelles | Head of Research and Dev. | 2026-02-17 | D | 2,728 | 12 | 31,647 | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-02-17 | D | 6,395 | 12 | 74,188 | Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-02-17 | D | 6,065 | 12 | 70,359 | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-04-23 | D | 8,889 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-04-23 | D | 18,978 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-04-23 | D | 330,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-04-23 | D | 60,157 | — | — | Common | Form 4 ↗ |
| Garry Nicholson | Director | 2026-04-23 | D | 33,900 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William Grossman | Director | 2026-04-23 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William Grossman | Director | 2026-04-23 | D | 32,335 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Habib Dable | Director | 2026-04-23 | D | 32,335 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Habib Dable | Director | 2026-04-23 | D | 66,660 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Garland | Director | 2026-04-23 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Garland | Director | 2026-04-23 | D | 32,335 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Josey | Director | 2026-04-23 | D | 1,181 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-04-23 | D | 32,335 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-04-23 | D | 37,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2026-04-23 | D | 32,335 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2026-04-23 | D | 37,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2026-04-23 | D | 40,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-04-23 | D | 25,816 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-04-23 | D | 5,250 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-04-23 | D | 90,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-04-23 | D | 46,375 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-04-23 | D | 116,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-04-23 | D | 151,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-04-23 | D | 497,667 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Vasconcelles | Head of Research and Dev. | 2026-04-23 | D | 106,875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Vasconcelles | Head of Research and Dev. | 2026-04-23 | D | 346,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Vasconcelles | Head of Research and Dev. | 2026-04-23 | D | 4,397 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 128,565 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 286,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 286,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 244,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 300,000 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 20,204 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 397,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 1,463,134 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William Grossman | Director | 2026-04-23 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William Grossman | Director | 2026-04-23 | D | 66,660 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Garland | Director | 2026-04-23 | D | 48,072 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Josey | Director | 2026-04-23 | D | 37,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2026-04-23 | D | 57,310 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 300,000 | — | — | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-04-23 | D | 40,565 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-04-23 | D | 90,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-04-23 | D | 90,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Garry Nicholson | Director | 2026-04-23 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Garry Nicholson | Director | 2026-04-23 | D | 37,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Josey | Director | 2026-04-23 | D | 72,292 | — | — | Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-04-23 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2026-04-23 | D | 40,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-04-23 | D | 40,565 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-04-23 | D | 90,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-04-23 | D | 162,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-04-23 | D | 162,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-04-23 | D | 312,025 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 355,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 808,285 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 147,702 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 204,643 | — | — | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-04-23 | D | 309,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-04-23 | D | 69,375 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-04-23 | D | 25,816 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-04-23 | D | 110,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Habib Dable | Director | 2026-04-23 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Josey | Director | 2026-04-23 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Josey | Director | 2026-04-23 | D | 32,335 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Josey | Director | 2026-04-23 | D | 28,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Josey | Director | 2026-04-23 | D | 63,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-04-23 | D | 118,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-04-23 | D | 72,875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Vasconcelles | Head of Research and Dev. | 2026-04-23 | D | 226,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Vasconcelles | Head of Research and Dev. | 2026-04-23 | D | 171,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 18,197 | — | — | Common | Form 4 ↗ |
| Habib Dable | Director | 2026-04-23 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| AI Day1 LLC | Greater-than-10% holder | 2026-04-23 | D | 12,929,322 | 22 | 277,980,423 | Common, indirect | Form 4 ↗ |
| Scott Garland | Director | 2026-04-23 | D | 28,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-04-23 | D | 28,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2026-04-23 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 81,816 | — | — | Derivative, Class A Common | Form 4 ↗ |
| AI Day1 LLC | Greater-than-10% holder | 2026-04-23 | D | 827,586 | 21 | 17,793,016 | Derivative, Class A Common | Form 4 ↗ |
| Garry Nicholson | Director | 2026-04-23 | D | 32,335 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-04-23 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-04-23 | D | 47,581 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2026-04-23 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-04-23 | D | 40,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2026-04-23 | D | 28,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-04-23 | D | 40,485 | — | — | Common | Form 4 ↗ |
| Scott Garland | Director | 2026-04-23 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Garland | Director | 2026-04-23 | D | 37,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Garry Nicholson | Director | 2026-04-23 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-04-23 | D | 65,625 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-04-23 | D | 105,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-04-23 | D | 90,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-04-23 | D | 72,694 | — | — | Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-04-23 | D | 188,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Josey | Director | 2026-04-23 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-04-23 | D | 6,750 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 222,188 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 14,250 | — | — | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 200 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Scott Garland | Director | 2025-11-06 | A | 28,700 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2025-11-06 | A | 309,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2025-11-06 | A | 32,335 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2025-11-06 | A | 32,335 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2025-11-06 | A | 37,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2025-11-06 | A | 28,700 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Garland | Director | 2025-11-06 | A | 48,072 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2025-11-06 | A | 40,300 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Garry Nicholson | Director | 2025-11-06 | A | 32,335 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Garry Nicholson | Director | 2025-11-06 | A | 37,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2025-11-06 | A | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-15 | D | 11,687 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-15 | D | 4,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-15 | A | 11,687 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-15 | A | 4,750 | — | — | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2025-11-15 | A | 3,687 | — | — | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2025-11-15 | A | 3,162 | — | — | Common | Form 4 ↗ |
| Charles York | COO and CFO | 2025-11-15 | D | 6,625 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2025-11-15 | D | 6,625 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2025-11-15 | D | 2,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2025-11-15 | D | 1,375 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2025-11-15 | A | 2,250 | — | — | Common | Form 4 ↗ |
| Charles York | COO and CFO | 2025-11-15 | A | 1,375 | — | — | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2025-11-15 | D | 1,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2025-11-15 | A | 3,687 | — | — | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2025-11-15 | A | 3,687 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-15 | D | 11,687 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-15 | A | 3,570 | — | — | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2025-11-15 | D | 3,687 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2025-11-15 | D | 3,687 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2025-11-15 | D | 2,963 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2025-11-15 | A | 3,687 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-15 | A | 11,687 | — | — | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2025-11-15 | D | 3,687 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2025-11-15 | D | 3,162 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2025-11-15 | A | 1,750 | — | — | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2025-11-15 | A | 2,963 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-15 | D | 3,570 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2025-11-15 | D | 3,687 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2025-11-15 | A | 6,625 | — | — | Common | Form 4 ↗ |
| Charles York | COO and CFO | 2025-11-15 | A | 6,625 | — | — | Common | Form 4 ↗ |
| Charles York | COO and CFO | 2025-11-17 | D | 4,062 | 9 | 36,212 | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2025-11-17 | D | 3,726 | 9 | 33,216 | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2025-11-17 | D | 4,319 | 9 | 38,503 | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-17 | D | 15,894 | 9 | 141,690 | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-25 | A | 300,000 | 0 | 0 | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-25 | A | 300,000 | 0 | 0 | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-25 | D | 7,225 | 0 | 0 | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-25 | D | 7,225 | 0 | 0 | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-25 | D | 300,000 | 0 | 0 | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2025-11-25 | D | 300,000 | 0 | 0 | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-01-30 | A | 110,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Vasconcelles | Head of Research and Dev. | 2026-01-30 | A | 114,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-01-30 | A | 74,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-01-30 | A | 355,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Vasconcelles | Head of Research and Dev. | 2026-01-30 | A | 171,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-01-30 | A | 126,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-01-30 | A | 188,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-01-30 | A | 237,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-01-30 | A | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-01-30 | A | 105,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-02-15 | D | 11,687 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-02-15 | D | 11,688 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-02-15 | A | 14,812 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-02-15 | A | 4,750 | — | — | Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-02-15 | D | 7,875 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-02-15 | D | 6,625 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-02-15 | D | 2,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-02-15 | A | 7,875 | — | — | Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-02-15 | A | 6,625 | — | — | Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-02-15 | A | 2,250 | — | — | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-02-15 | D | 3,687 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-02-15 | D | 1,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-02-15 | A | 3,688 | — | — | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-02-15 | D | 4,625 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-02-15 | A | 3,687 | — | — | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-02-15 | A | 3,688 | — | — | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-02-15 | D | 3,688 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-02-15 | A | 3,687 | — | — | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-02-15 | D | 3,162 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Vasconcelles | Head of Research and Dev. | 2026-02-15 | D | 7,125 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Vasconcelles | Head of Research and Dev. | 2026-02-15 | A | 7,125 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-02-15 | D | 4,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-02-15 | A | 11,687 | — | — | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-02-15 | A | 4,375 | — | — | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-02-15 | A | 1,750 | — | — | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-02-15 | D | 4,375 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-02-15 | D | 3,687 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-02-15 | D | 3,688 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-02-15 | A | 3,162 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-02-15 | D | 14,812 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-02-15 | A | 4,625 | — | — | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-02-15 | D | 2,963 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-02-15 | D | 6,625 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-02-15 | A | 2,963 | — | — | Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-02-15 | A | 6,625 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-02-15 | A | 11,688 | — | — | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-02-17 | D | 5,814 | 12 | 67,448 | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-02-17 | D | 15,459 | 12 | 179,338 | Common | Form 4 ↗ |
| Michael Vasconcelles | Head of Research and Dev. | 2026-02-17 | D | 2,728 | 12 | 31,647 | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-02-17 | D | 6,395 | 12 | 74,188 | Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-02-17 | D | 6,065 | 12 | 70,359 | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-04-23 | D | 8,889 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-04-23 | D | 18,978 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-04-23 | D | 330,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-04-23 | D | 60,157 | — | — | Common | Form 4 ↗ |
| Garry Nicholson | Director | 2026-04-23 | D | 33,900 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William Grossman | Director | 2026-04-23 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William Grossman | Director | 2026-04-23 | D | 32,335 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Habib Dable | Director | 2026-04-23 | D | 32,335 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Habib Dable | Director | 2026-04-23 | D | 66,660 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Garland | Director | 2026-04-23 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Garland | Director | 2026-04-23 | D | 32,335 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Josey | Director | 2026-04-23 | D | 1,181 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-04-23 | D | 32,335 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-04-23 | D | 37,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2026-04-23 | D | 32,335 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2026-04-23 | D | 37,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2026-04-23 | D | 40,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-04-23 | D | 25,816 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-04-23 | D | 5,250 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-04-23 | D | 90,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-04-23 | D | 46,375 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-04-23 | D | 116,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-04-23 | D | 151,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-04-23 | D | 497,667 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Vasconcelles | Head of Research and Dev. | 2026-04-23 | D | 106,875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Vasconcelles | Head of Research and Dev. | 2026-04-23 | D | 346,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Vasconcelles | Head of Research and Dev. | 2026-04-23 | D | 4,397 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 128,565 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 286,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 286,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 244,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 300,000 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 20,204 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 397,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 1,463,134 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William Grossman | Director | 2026-04-23 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William Grossman | Director | 2026-04-23 | D | 66,660 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Garland | Director | 2026-04-23 | D | 48,072 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Josey | Director | 2026-04-23 | D | 37,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2026-04-23 | D | 57,310 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 300,000 | — | — | Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-04-23 | D | 40,565 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-04-23 | D | 90,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-04-23 | D | 90,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Garry Nicholson | Director | 2026-04-23 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Garry Nicholson | Director | 2026-04-23 | D | 37,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Josey | Director | 2026-04-23 | D | 72,292 | — | — | Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-04-23 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2026-04-23 | D | 40,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-04-23 | D | 40,565 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-04-23 | D | 90,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-04-23 | D | 162,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-04-23 | D | 162,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-04-23 | D | 312,025 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 355,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 808,285 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 147,702 | — | — | Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 204,643 | — | — | Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-04-23 | D | 309,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-04-23 | D | 69,375 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-04-23 | D | 25,816 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lauren Merendino | Chief Commercial Officer | 2026-04-23 | D | 110,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Habib Dable | Director | 2026-04-23 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Josey | Director | 2026-04-23 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Josey | Director | 2026-04-23 | D | 32,335 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Josey | Director | 2026-04-23 | D | 28,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Josey | Director | 2026-04-23 | D | 63,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-04-23 | D | 118,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-04-23 | D | 72,875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Vasconcelles | Head of Research and Dev. | 2026-04-23 | D | 226,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Vasconcelles | Head of Research and Dev. | 2026-04-23 | D | 171,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 18,197 | — | — | Common | Form 4 ↗ |
| Habib Dable | Director | 2026-04-23 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| AI Day1 LLC | Greater-than-10% holder | 2026-04-23 | D | 12,929,322 | 22 | 277,980,423 | Common, indirect | Form 4 ↗ |
| Scott Garland | Director | 2026-04-23 | D | 28,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-04-23 | D | 28,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2026-04-23 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 81,816 | — | — | Derivative, Class A Common | Form 4 ↗ |
| AI Day1 LLC | Greater-than-10% holder | 2026-04-23 | D | 827,586 | 21 | 17,793,016 | Derivative, Class A Common | Form 4 ↗ |
| Garry Nicholson | Director | 2026-04-23 | D | 32,335 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-04-23 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-04-23 | D | 47,581 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2026-04-23 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-04-23 | D | 40,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Natalie Holles | Director | 2026-04-23 | D | 28,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-04-23 | D | 40,485 | — | — | Common | Form 4 ↗ |
| Scott Garland | Director | 2026-04-23 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Scott Garland | Director | 2026-04-23 | D | 37,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Garry Nicholson | Director | 2026-04-23 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-04-23 | D | 65,625 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-04-23 | D | 105,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-04-23 | D | 90,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Adam Dubow | Gen Counsel & Secretary | 2026-04-23 | D | 72,694 | — | — | Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-04-23 | D | 188,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| John Josey | Director | 2026-04-23 | D | 22,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles York | COO and CFO | 2026-04-23 | D | 6,750 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 222,188 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeremy Bender | Director | 2026-04-23 | D | 14,250 | — | — | Derivative, Class A Common | Form 4 ↗ |
Sources (227 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Jeremy Bender. DEF 14A, filed 2025-04-11. Section “Executive Compensation” · page 43. As printed: 6,560,577. View filing ↗
- Section 01, Charles York. DEF 14A, filed 2025-04-11. Section “Executive Compensation”. As printed: 3,896,080. View filing ↗
- Section 01, Samuel Blackman. DEF 14A, filed 2025-04-11. Section “Executive Compensation”. As printed: 3,614,904. View filing ↗
- Section 01, Adam Dubow. DEF 14A, filed 2025-04-11. Section “Executive Compensation”. As printed: 2,385,614. View filing ↗
- Section 03, Charles York OPTION. DEF 14A, filed 2025-04-11. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jeremy Bender RSU. DEF 14A, filed 2025-04-11. Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Samuel Blackman RSU. DEF 14A, filed 2025-04-11. Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Adam Dubow RSU. DEF 14A, filed 2025-04-11. Section “TABLE OF CONTENTS EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Charles York RSU. DEF 14A, filed 2025-04-11. Section “TABLE OF CONTENTS REPORT OF THE COMPENSATION COMMITTEE” · grants of plan-based awards table. View filing ↗
- Section 03, Samuel Blackman OPTION. DEF 14A, filed 2025-04-11. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jeremy Bender OPTION. DEF 14A, filed 2025-04-11. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Adam Dubow OPTION. DEF 14A, filed 2025-04-11. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2025-04-11. Section “CEO Pay Ratio”. As printed: 17 : 1. View filing ↗
- Section 08, William Grossman. DEF 14A, filed 2025-04-11. Section “Director Compensation”. As printed: 911,897. View filing ↗
- Section 08, Habib Dable. DEF 14A, filed 2025-04-11. Section “Director Compensation”. As printed: 910,022. View filing ↗
- Section 08, Garry Nicholson. DEF 14A, filed 2025-04-11. Section “Director Compensation”. As printed: 363,475. View filing ↗
- Section 08, Saira Ramasastry. DEF 14A, filed 2025-04-11. Section “Director Compensation”. As printed: 340,350. View filing ↗
- Section 08, Natalie Holles. DEF 14A, filed 2025-04-11. Section “Director Compensation”. As printed: 337,850. View filing ↗
- Section 08, John Josey. DEF 14A, filed 2025-04-11. Section “Director Compensation”. As printed: 332,225. View filing ↗
- Section 08, Scott Garland. DEF 14A, filed 2025-04-11. Section “Director Compensation”. As printed: 330,350. View filing ↗
- Section 08, Michael Gladstone. DEF 14A, filed 2025-04-11. Section “Director Compensation”. As printed: 330,350. View filing ↗
- Section 08, Daniel Becker. DEF 14A, filed 2025-04-11. Section “Director Compensation”. As printed: 18,736. View filing ↗
- Section 08, Jeremy Bender. DEF 14A, filed 2025-04-11. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Scott Garland 2025-11-06. Form 4, filed 2025-11-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2025-11-06. Form 4, filed 2025-11-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Saira Ramasastry 2025-11-06. Form 4, filed 2025-11-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Natalie Holles 2025-11-06. Form 4, filed 2025-11-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Natalie Holles 2025-11-06. Form 4, filed 2025-11-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Natalie Holles 2025-11-06. Form 4, filed 2025-11-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Garland 2025-11-06. Form 4, filed 2025-11-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Natalie Holles 2025-11-06. Form 4, filed 2025-11-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Garry Nicholson 2025-11-06. Form 4, filed 2025-11-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Garry Nicholson 2025-11-06. Form 4, filed 2025-11-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Natalie Holles 2025-11-06. Form 4, filed 2025-11-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2025-11-15. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2025-11-17. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2025-11-17. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2025-11-17. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2025-11-17. Form 4, filed 2025-11-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2025-11-25. Form 4, filed 2025-11-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2025-11-25. Form 4, filed 2025-11-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2025-11-25. Form 4, filed 2025-11-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2025-11-25. Form 4, filed 2025-11-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2025-11-25. Form 4, filed 2025-11-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2025-11-25. Form 4, filed 2025-11-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2026-01-30. Form 4, filed 2026-01-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Vasconcelles 2026-01-30. Form 4, filed 2026-01-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2026-01-30. Form 4, filed 2026-01-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-01-30. Form 4, filed 2026-01-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Vasconcelles 2026-01-30. Form 4, filed 2026-01-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2026-01-30. Form 4, filed 2026-01-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2026-01-30. Form 4, filed 2026-01-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-01-30. Form 4, filed 2026-01-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-01-30. Form 4, filed 2026-01-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-01-30. Form 4, filed 2026-01-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Vasconcelles 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Vasconcelles 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-02-15. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2026-02-17. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-02-17. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Vasconcelles 2026-02-17. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-02-17. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2026-02-17. Form 4, filed 2026-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Garry Nicholson 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Grossman 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Grossman 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Habib Dable 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Habib Dable 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Garland 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Garland 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Josey 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Saira Ramasastry 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Saira Ramasastry 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Natalie Holles 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Natalie Holles 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Natalie Holles 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Vasconcelles 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Vasconcelles 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Vasconcelles 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Grossman 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Grossman 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Garland 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Josey 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Natalie Holles 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Garry Nicholson 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Garry Nicholson 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Josey 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Saira Ramasastry 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Natalie Holles 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lauren Merendino 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Habib Dable 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Josey 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Josey 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Josey 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Josey 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Vasconcelles 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Vasconcelles 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Habib Dable 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, AI Day1 LLC 2026-04-23. Form 4, filed 2026-04-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Garland 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Saira Ramasastry 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Natalie Holles 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, AI Day1 LLC 2026-04-23. Form 4, filed 2026-04-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Garry Nicholson 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Saira Ramasastry 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Saira Ramasastry 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Natalie Holles 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Saira Ramasastry 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Natalie Holles 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Saira Ramasastry 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Garland 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Garland 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Garry Nicholson 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Dubow 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Josey 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles York 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeremy Bender 2026-04-23. Form 4, filed 2026-04-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 471,055 + equity 0 + all other 0 = 471,055, summed across the director compensation table rows.
- Day One Biopharmaceuticals, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2025-04-11. CEO total compensation as printed in Day One Biopharmaceuticals, Inc.'s own proxy. As printed: 6,560,577. View filing ↗